Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 03 entities : Myriad genetics, inc. save search
Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
Published: 2021-05-03 (Crawled : 21:00) - globenewswire.com
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.5%
H: 2.03%
C: 1.83%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.39%
H: 5.68%
C: 4.43%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: -1.5%
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -2.25%
H: 0.43%
C: -0.74%
genetic ev growth liver
Labcorp to Acquire Myriad Autoimmune’s Vectra Testing Business From Myriad Genetics
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.8%
H: 0.71%
C: -0.25%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 2.12%
H: 0.0%
C: -1.49%
genetic test
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 2.12%
H: 0.0%
C: -1.49%
genetic growth
Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.8%
H: 0.71%
C: -0.25%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 2.12%
H: 0.0%
C: -1.49%
genetic test
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.